Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Strategic Expansion into AI-Powered Healthcare Solutions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Profound Medical Corp T.PRN

Alternate Symbol(s):  PROF

Healthcare Medical Devices
Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum. TULSA-PRO has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer and the transition zone in large volume benign prostatic hyperplasia. It is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.


TSX:PRN - Post by User

Profound Medical Corp
Bullboard Posts
User Avatar Image
(3)
•••
Comment by seajuston Nov 18, 2015 5:51pm
84 Views
Post# 24302952

RE:CFO is gone...out of there...

RE:CFO is gone...out of there...and a larger trade today too....... 2015-10-28 04:14 PRN 0.95 News Release Profound Medical to issue Q3 results Nov. 4 Recent Trades - All 9 today Time ET Ex Price Change Volume Buyer Seller Markers 15:53:14 V 0.85 -0.01 400 1 Anonymous 80 National Bank 15:53:07 V 0.85 -0.01 500 1 Anonymous 1 Anonymous K 15:33:46 V 0.85 -0.01 500 80 National Bank 1 Anonymous K 15:33:46 V 0.85 -0.01 100,000 79 CIBC 1 Anonymous K 13:15:51 V 0.86 2,000 9 BMO Nesbitt 1 Anonymous K 13:14:25 V 0.80 -0.06 500 1 Anonymous 2 RBC K 12:21:45 V 0.83 -0.03 100 86 Pictet 80 National Bank 12:21:45 V 0.83 -0.03 500 1 Anonymous 2 RBC KL
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities